Establishment Labs Holdings Inc. announced the presentation of three-year clinical results for Mia Femtech™ at the 9th Annual World Symposium on Ergonomic Implants. The study enrolled 100 subjects between December 2020 and April 2021, with a follow-up compliance rate of 93% at three years.
The preliminary analysis of key complications showed no reports of capsular contracture (Baker Grade III/IV) and no ruptures, suspected or confirmed. Additionally, there were no reports of infection, hematoma, seroma requiring intervention, or changes in nipple or breast sensation.
Juan José Chacón-Quirós, Founder and CEO, stated that these Mia results are among the best breast implant data reported at three years, proving that minimally invasive procedures are the future of breast aesthetics. The company has begun the process to bring this technology to the United States following the recent FDA approval of Motiva implants.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.